FABPulous wins €1.6m EU grant for clinical trials of 5 minute heart attack test

Date: 21/07/2015

20 July 2015, Maastricht (Netherlands) – The European Union awarded FABPulous BV a €1.6 million Phase 2 grant to fund two clinical trials in the UK and Belgium/Netherlands and automate the manufacture of its 5 minute, patented H-FABP True Rapid Test®, which helps emergency medical workers quickly distinguish whether a patient with chest pain is at risk of a heart attack.

Between 1-2% of the population complains of chest pain every year. In emergency medicine, typically 60% of those patients will be diagnosed as potentially at risk of heart disease and most will be admitted to hospital for observation under the current guidelines for health care systems such as Britain’s NHS. But only 15-20% of these patients will be finally diagnosed with Acute Myocardial Infarction (AMI), or heart attack. That means wasted beds in overstretched hospitals, unnecessary tests, demands on hospital staff, increased waiting times and rising pressure on the resources of health care providers. The EU grant will help FABPulous produce the necessary clinical evidence to support the adoption of its 5 minute H-FABP True Rapid Test as a way for emergency medical workers to rule out heart attacks before they are required to admit patients to hospital.

“This EU grant brings FABPulous a step closer to producing the crucial tool that will rule out heart attack as a risk for a significant number of patients with chest pain, dramatically cutting unnecessary admissions whilst reducing stress for patients,” said FABPulous Chief Executive Officer Conor O’Brien.

The grant funding supplied by the EU’s H-2020 SME Instrument will also allow FABPulous to develop semi-automated manufacturing processes of reproducible quality, to increase manufacturing capacity of the H-FABP True Rapid Test and improve its affordability. H-FABP True Rapid Test is a whole blood IVD device that is capable of providing reliable detection of the Heart-type Fatty Acid Binding Protein (H-FABP), a small myocardial protein that is quickly detectable in capillary blood after a heart attack. H-FABP True Rapid Test combines a rapid, equipment free, sample preparation device with an immunoassay test that can be used during the moment of patient/clinician contact at point of care to help provide the necessary clinical evidence to discharge low risk patients earlier with minimal risk. The test can be done within 5 minutes without the need for instrumentation and is simple enough for non-technical nursing staff to run and interpret.  FABPulous is a venture capital-backed company that was spun out of Maastricht University at the end of 2008. FABPulous develops and markets pioneering Point of Care (PoC) solutions for better diagnostics in primary care and emergency medicine.

About Horizon 2020 SME Instrument

As part of the Horizon 2020 programme, the European Commission is selecting potentially disruptive businesses to invest in and support as part of the SME Instrument. SMEs with a strong growth potential and the ambition to become world-market leaders can receive up to €2.5 million in funding, and world-class business support and mentoring. The instrument is structured in three phases, with the aim of transforming disruptive ideas into concrete, innovative solutions with a European and global impact. The Phase 2 projects covering Demonstration, Market Replication, R&D Concept to Market-Maturity over a period of 1-2 years are aimed to help the SME further develop its proposal through innovation activities, and draft a more developed business plan. For more information visit:

The full press release can be found here.